Previous 10 | Next 10 |
home / stock / mycof / mycof news
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has entered into...
Biotechnology company Mydecine Innovations Group ( OTCPK:MYCOF ) said it has entered into a share subscription agreement with a third party investor and that the current CFO has resigned. The investor has subscribed for ~327M shares at $0.75 per share for aggregate gross proce...
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder (“PTSD”). The comp...
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly addr...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is basically shutting down as the company has burned through its cash and is closing its research operations in Denver Colorado. The psilocybin company reported financial results for the six months ending June 30, 2022, with ...
Mydecine Innovations Group press release ( OTCPK:MYCOF ): Q2 GAAP EPS of -C$0.35. The Company had C$324,146 in cash and cash equivalents as of June 30, 2022. For further details see: Mydecine Innovations Group GAAP EPS of -C$0.35
DENVER, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results for the six months en...
MYDECINE INNOVATIONS GROUP ANNOUNCES RESIGNATION OF DIRECTORS Canada NewsWire DENVER , Aug. 12, 2022 /CNW/ - Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the ne...
News, Short Squeeze, Breakout and More Instantly...
New Age Brands Company Name:
MYCOF Stock Symbol:
OTCMKTS Market:
(TheNewswire) VANCOUVER, British Columbia – TheNewswire - April 25, 2024 — Mydecine Innovations Group Inc. (the “ Company ”) (CSE:MYCO) (FSE:0NF0) (OTC:MYCOF) (AQSE:MYIG) announces that as a result of a review by the British Columbia...
(TheNewswire) VANCOUVER, BC – TheNewswire - (15 April 2024 ) Mydecine Innovations Group Inc . (CSE: MYCO) (AQSE: MYIG) (FSE: 0NFA) (OTC: MYCOF) (the “ Company ” or “ Mydecine ”) announces that it has closed two d...
(TheNewswire) V ANCOUVER, BC – ( TheNewswire / 27 March 2024 ) Mydecine Innovations Group Inc . (CSE: MYCO) (AQSE: MYIG) (FSE: 0NFA) (OTC: MYCOF) (the “ Company ” or “ Mydecine ”) announces that it has closed...